- JP-listed companies
- Balance sheet
(4888) Balance sheet
Market cap
¥11B
P/E ratio
-18.8x
Develops BNCT cancer treatment that uses boron and neutrons to selectively destroy cancer cells while minimizing damage to healthy tissue.
| 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Cash and cash equivalents | - | 2,991 | 2,007 | 1,251 | 3,276 | 2,710 | 2,053 | 3,206 | 2,823 |
| Marketable securities, current | - | - | - | - | - | - | 301 | - | - |
| Total current assets | - | 3,362 | 2,401 | 1,811 | 4,175 | 3,793 | 3,629 | 5,243 | 4,353 |
| Property, plant and equipment, net | - | 63 | 68 | 68 | 92 | 103 | 82 | 67 | 47 |
| Marketable securities, non-current | - | - | - | - | 305 | 303 | - | - | - |
| Total non-current assets | - | 260 | 259 | 238 | 543 | 536 | 191 | 174 | 134 |
| Total assets | - | 3,622 | 2,660 | 2,049 | 4,719 | 4,329 | 3,821 | 5,417 | 4,487 |
| Long-term debt, current | - | - | 160 | 160 | 160 | 160 | 160 | 159 | 159 |
| Total current liabilities | - | 114 | 308 | 319 | 308 | 422 | 456 | 390 | 260 |
| Total non-current liabilities | - | 1,856 | 1,662 | 1,499 | 1,331 | 1,155 | 988 | 1,819 | 1,800 |
| Total liabilities | - | 1,970 | 1,970 | 1,818 | 1,639 | 1,577 | 1,444 | 2,210 | 2,060 |
| Retained earnings | - | -948 | -1,210 | -1,869 | -2,637 | -779 | -764 | -141 | -781 |
| Stockholders' equity | 2,511 | 1,652 | 690 | 231 | 3,080 | 2,753 | 2,377 | 3,207 | 2,427 |